Originally published In Press as doi:10.1074/jbc.M202753200 on June 12, 2002
J. Biol. Chem., Vol. 277, Issue 34, 31249-31256, August 23, 2002
Protein Kinase A-mediated Phosphorylation of the
2-Adrenergic Receptor Regulates Its Coupling to
Gs and Gi
DEMONSTRATION IN A RECONSTITUTED SYSTEM*
A. Musa
Zamah
,
Martha
Delahunty§,
Louis M.
Luttrell§¶, and
Robert J.
Lefkowitz
§
**
From
The Howard Hughes Medical Institute and the Departments
of § Medicine and
Biochemistry, Duke
University Medical Center, Durham, North Carolina 27710 and ¶ The
Geriatrics Research, Education and Clinical Center, Durham Veterans
Affairs Medical Center, Durham, North Carolina 27705
Received for publication, March 21, 2002, and in revised form, June 5, 2002
 |
ABSTRACT |
While classically viewed as a prototypic
Gs and adenylyl cyclase-coupled G protein-coupled
receptor, recent studies have indicated that some aspects of
2-adrenergic receptor (
2-AR) signaling are inhibited by pertussis toxin, indicating that they are mediated by
Gi/Go proteins. These signals include
activation of ERK MAPKs and Akt activation, as well as
hypertrophic and anti-apoptotic pathways in cardiac myocytes. Studies
in cultured cells have suggested the hypothesis that protein kinase A
(PKA)-mediated phosphorylation of the
2-AR regulates its
coupling specificity with respect to Gs and Gi.
Using a Chinese hamster ovary cell system, we show that mutant
2-ARs with Ala substituted for Ser at consensus PKA sites stimulate robust cyclic AMP accumulation (Gs) but are
unable to activate ERK (Gi). In contrast, Ser
Asp mutants are dramatically impaired in their ability to
activate adenylyl cyclase but are significantly more active than wild
type receptor in activating ERK. Activation of adenylyl cyclase by wild
type and Ser
Ala mutant receptors is not altered by pertussis
toxin, whereas adenylyl cyclase stimulated through the Ser
Asp
mutant is enhanced. Activation of ERK by wild type and Ser
Asp
receptors is inhibited by pertussis toxin. To further rigorously test
the hypothesis, we utilized a completely reconstituted system of
purified recombinant wild type and PKA phosphorylation site
mutant
2-ARs and heterotrimeric Gs and
Gi. G protein coupling was measured by receptor-mediated stimulation of GTP
S binding to the G protein. PKA-mediated
phosphorylation of the
2-AR significantly
decreased its ability to couple to Gs, while simultaneously
dramatically increasing its ability to couple to Gi. These
results are reproduced when a purified recombinant Ser
Asp mutant
2-AR is tested, whereas the Ser
Ala receptor resembles the unphosphorylated wild type. These results provide strong
experimental support for the idea that PKA-mediated phosphorylation of
the
2-adrenergic receptor switches its predominant
coupling from Gs to Gi.
 |
INTRODUCTION |
The
2-adrenergic receptor
(
2-AR)1 is a well characterized
member of a large, diverse family of cell
surface receptors referred to as seven membrane-spanning or G
protein-coupled receptors (GPCRs). One of the primary ways in which
members of this receptor super-family generate signal specificity is by
interacting predominantly with one member or a subset of members of the
heterotrimeric G protein family. Prior studies of the
2-AR in both reconstituted and cellular systems have
shown that it is primarily coupled to Gs and thereby linked
to stimulation of adenylate cyclase activity and to important physiological processes such as increased cardiac chronotropy and
inotropy and relaxation of vascular and bronchial smooth muscle (1-4).
However, certain other aspects of
2-AR signaling appear to be mediated via pertussis toxin-sensitive Gi proteins.
These signals include ERK 1/2 activation, receptor tyrosine kinase
transactivation, and Akt activation (5-7). The important physiological
consequences of these signals include both hypertrophic and
anti-apoptotic pathways in cultured cardiac myocytes (8).
Recent cellular studies have suggested that the pertussis
toxin-sensitive Gi-mediated activation of ERK by
2-ARs is nonetheless dependent on
Gs-mediated protein kinase A (PKA) activation, because a
chemical inhibitor of PKA (H-89) blocks ERK activation by the
2-AR in HEK 293 cells. Furthermore, because a mutant
2-AR, which cannot be phosphorylated by PKA, is
deficient in ERK activation, it has been suggested that the receptor
itself must be phosphorylated by PKA to effectively couple to
Gi (5). However, definitive assessment of this hypothesis
cannot be achieved in the complex environment of an intact cell.
An increasing number of heptahelical receptors are now known to be
capable of coupling to more than one type of heterotrimeric G protein
(9). But almost nothing is known about the molecular mechanisms that
might regulate the relative efficacy of coupling of a particular
receptor with different G proteins. Accordingly, here we examine, in a
completely reconstituted system, the hypothesis that the coupling of
2-ARs to the two G proteins, Gs and
Gi, is regulated by PKA-mediated phosphorylation of the
receptor. This work, carried out both with purified recombinant wild
type
2-AR, phosphorylated in vitro by PKA, as
well as with purified recombinant mutant receptors that mimic the
phosphorylated form of the receptors, provides definitive evidence that
PKA phosphorylation of the
2-AR can regulate its
coupling efficiency to both Gs and Gi.
Moreover, these results expand the previously documented role of
PKA-mediated phosphorylation of the
2-AR to desensitize
the receptor's ability to couple to Gs, demonstrating that
enhanced coupling of the receptor to Gi may be an equally
important physiological consequence of this phosphorylation event.
 |
EXPERIMENTAL PROCEDURES |
Materials--
All tissue culture reagents were from Invitrogen
unless otherwise noted. Pertussis toxin was from List Biological
Laboratories. ICI-118,551 was from Research Biochemicals International.
[35S]GTP
S and 125I-cyanopindolol
were purchased from PerkinElmer Life Sciences. Recombinant
His6-TEV protease was purchased from Invitrogen. All other
chemicals were purchased from Sigma Chemical Co. except where noted.
Plasmids--
The N-terminal FLAG epitope-tagged human wild type
and A-4 (S261A/S262A/S345A/S346A)
2-AR were
cloned into a modified pBKCMV as previously described (10). The
N-terminal FLAG epitope-tagged D-4 (S261D/S262D/S345D/S346D)
2-AR was created by PCR mutagenesis and confirmed by ABI
sequencing. For Sf9 expression, the N-terminal FLAG
epitope-tagged wild type, A-4 and D-4
2-AR were cloned
into pVL1392 (BD PharMingen) with the addition of a His6
C-terminal tag to facilitate purification.
Creation of Chinese Hamster Ovary
2-AR-expressing
Stable Lines--
Chinese hamster ovary (CHO) cells were grown and
maintained in Ham's F-12 media (Invitrogen) supplemented with 10%
(v/v) fetal calf serum and antibiotics (1% penicillin (10 units/ml)/streptomycin (10 mg/ml)) at 37 °C in a humidified 5%
CO2 atmosphere. The DNA used to create the stable cell
lines was either the N-terminal FLAG-tagged wild type, A-4 mutant, or
D-4 mutant
2-AR in a modified pBKCMV vector. Cells in
10-cm tissue culture plates were transfected using 5 µg of total DNA
and a 3:1 ratio of FuGENE (Roche Molecular Biochemicals) reagent
according to the manufacturer's protocol. The cells were given fresh
media every 3 days in the presence of 0.5 mg/ml Geneticin until single
colonies could be isolated. Single colonies were expanded and screened
for stable overexpression of the
2-AR using
125I-(
)-cyanopindolol binding assays to crude membranes
(11), with bound and free radioligand separated by filtration over
24-mm GF/C glass microfiber filters (Whatman).
Phospho-ERK Assays--
Stably transfected CHO cells in six-well
plates were grown in serum starvation media containing 0.1% bovine
serum albumin and 10 mM Hepes, pH 7.4, for 16 h prior
to agonist stimulation. Where indicated, cells were treated with
pertussis toxin (PTX) 100 ng/ml for 16 h prior to agonist
stimulation. The cells were stimulated with the appropriate agonist for
5 min at 37 °C, and the reactions were terminated by direct addition
of 250 µl of 2× Laemmli sample buffer to cell monolayers. The cell
lysates were sonicated for 10 s, boiled for 10 min, and clarified
by brief centrifugation at 20,000 × g. The samples
were then electrophoresed on 4-20% gradient SDS-PAGE gels and
transferred to a polyvinylidene fluoride membrane. Phospho-ERK was
detected using a 1:1000 dilution of a rabbit polyclonal anti-phospho
p44/42 ERK-specific antibody (Cell Signaling Technology). Duplicate
gels were used to blot for total ERK expression in the lysate using a
rabbit polyclonal anti-ERK 1/2 antibody (Upstate Biotechnology,
1:2000). The blots were washed in 10 mM Tris, pH 7.0/150
mM NaCl/0.05% v/v Tween 20/0.05% (v/v) Nonidet P-40
(TBS-T) and incubated with a 1:7000 dilution of secondary donkey
anti-rabbit IgG conjugated to horseradish peroxidase (Jackson
Laboratories) for 1 h at room temperature. The blots were
visualized by chemiluminescence using SuperSignal reagent (Pierce)
according to the manufacturer's instructions. Quantitation of the
images was performed using a Fluor-S Multiimager with Quantity One
software (Bio-Rad).
Adenylyl Cyclase Assays--
Attached cells were washed twice
with phosphate-buffered saline, scraped, and lysed by Dounce
homogenization. Unlysed cells and nuclei were removed by centrifugation
at 500 × g for 5 min at 4 °C, and the supernatant
was centrifuged at 40,000 × g for 30 min. Pelleted
membranes were washed twice and resuspended in 75 mM Tris,
pH 7.4, 12.5 mM MgCl2, 2 mM EDTA
buffer. Adenylyl cyclase activities were determined as previously
described (12). Reactions were initiated by the addition of membranes
to the assay mixtures and incubated for 15 min at 37 °C.
Determinations were performed in triplicate.
Cyclic AMP Determination--
Cells were grown to ~80%
confluence in six-well dishes in media containing 0.25 mg/ml Geneticin,
and where indicated PTX (100 ng/ml) was added 16 h prior to
agonist stimulation. The cells were rinsed once in serum-free media and
then treated with 1 mM 3-isobutyl-1-methylxanthine (IBMX)
for 5 min prior to stimulation to inhibit phosphodiesterases. Cells
were stimulated for 10 min at 37 °C with the indicated concentration
of (
)-isoproterenol in the presence of 1 mM IBMX and 0.4 mM ascorbate. Forskolin (10 µM) was used as a
positive control. To terminate stimulation, the media was aspirated and
200 µl of ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4/4
mM EDTA) was added to each well, and the samples were
placed on ice. The cells were detached by scraping, and protein
concentration was determined by the Bradford assay (Bio-Rad). The
samples were boiled for 10 min, centrifuged for 1 min at 14,000 × g, and frozen overnight at
100 °C for subsequent determination of cAMP levels. The levels of cAMP were determined using
a 3H-labeled cAMP assay system (Amersham
Biosciences) according to the manufacturer's protocol. The final
results were expressed as picomoles of cAMP/mg of protein.
2-AR Purification and Reconstitution--
The
human
2-adrenergic receptor (
2-AR) was
expressed and purified from baculovirus-infected Sf9 cells as
described previously (13). The wild type and PKA point mutant receptors
all contain an N-terminal FLAG epitope tag and a C-terminal
hexa-histidine tag to facilitate purification. Briefly, Sf9
cells were harvested by centrifugation 48 h post-infection with
the recombinant virus. The cells were lysed by Dounce homogenization,
and a membrane fraction was prepared by centrifugation at 33,000 × g for 30 min at 4 °C. The membranes were solubilized
with 0.25% (w/v) n-dodecyl
-D-maltoside and
purified by sequential chromatography using an
alprenolol-Sepharose column (14) with a procedure originally modified from a prior protocol (15), a subsequent nickel affinity column (13), and a final anion exchange Q-Sepharose column. The
purified receptor was assayed for its ability to bind
125I-cyanopindolol and reconstituted into crude soybean
phosphatidylcholine (20%) lipid vesicles using a modified protocol
(16). Briefly, the receptor and phospholipid were incubated with the
detergent n-octyl
-D-glucopyranoside (0.95%,
w/v) in a buffer containing 100 mM NaCl, 10 mM
Tris, pH 7.4, 20 mM MgCl2 on ice and
subsequently eluted over a detergent-removing Extracti-gel column
(Pierce). The eluate was then treated with polyethylene glycol 8000 to
promote fusion of the nascent vesicles, followed by centrifugation at 150,000 × g for 2 h at 4 °C. The pelleted
vesicles were resuspended in 10 mM Tris-HCl, pH 7.4/100
mM NaCl and assayed for 125I-cyanopindolol
binding to determine efficiency of reconstitution and to enable
equivalent amounts of receptor to be used in the subsequent
experiments. Control vesicles were made by the same method but
excluding any receptor in the initial incubation period.
Purification of G Protein Subunits--
The
H6TEVpQE-60 plasmids containing either G
s or
G
i-1 were the generous gifts of A. Gilman (University of
Texas Southwestern). The recombinant G
subunits were grown in
Escherichia coli and purified as previously described (17).
The G
subunits were provided by D. Capel and were purified from
bovine brain, as previously described (18).
G protein Loading Assay--
Stoichiometric amounts of G
and
G
subunits were mixed and placed on ice. Vesicles containing the
reconstituted
2-AR protein were added to the
heterotrimeric G protein mixture on ice and incubated for 15-30 min.
The [35S]GTP
S binding buffer consisted of 20 mM Tris-HCl, pH 7.4, 10 mM MgCl2, 2 mM EDTA, and 0.1 mM ascorbate. A solution of 1 nM [35S]GTP
S was made using the binding
buffer (19). Typical specific activity of the radiolabeled
[35S]GTP
S mixture was 6,000-12,000 cpm/pmol. Each
binding reaction was performed in a 12- × 75-mm polypropylene tube
(Fisher) and consisted of 50 µl of the [35S]GTP
S and
8 µl of reconstituted receptor/G protein mixtures in the presence or
absence of 10 µM (
)-isoproterenol. Each reaction was
done in duplicate at 25 °C for the indicated time and quenched by
the addition of 5 ml of ice-cold quench buffer (20 mM
Tris-HCl, pH 7.4, 100 mM NaCl, 25 mM
MgCl2, and 1 µM GTP). The reactions were then
filtered using 0.45-µm BA-85 nitrocellulose membranes (Schleicher and
Schuell), as described previously (20, 21). The filters were washed six
times with 5 ml of quench buffer, placed in Lefkofluor scintillation
fluid, and counted in a Tri-Carb scintillation counter (Packard).
Background counts were determined from reactions lacking G protein in
the binding mixture. Control binding was determined by performing the
reaction with the heterotrimeric G protein with phospholipid vesicles
lacking the receptor to determine the baseline level of G protein
loading. The data were plotted using Prism (GraphPad Software Inc.) and
fit to a single-site hyperbolic binding curve.
In Vitro Phosphorylation Assays--
Purified recombinant
2-AR was reconstituted into phospholipid vesicles as
described above. A typical reaction used 3-5 pmol of receptor in a
final volume of 40 µl. The phosphorylation buffer contained 20 mM Tris-HCl, pH 7.4, 2 mM EDTA, 5 mM MgCl2, and 60 µM
[
-32P]ATP (~5000 cpm/pmol). For each reaction with
PKA, 0.5 µg of catalytic PKA subunit (Promega) was included. For GRK2
reactions, 0.4 µg of purified recombinant GRK2 was used, and the
phosphorylation buffer was supplemented with 10 µM
isoproterenol and 0.1 mM ascorbate (22). The reaction
was performed at 30 °C for 45 min and terminated by the addition of
400 µl of ice-cold 100 mM NaCl/10 mM
Tris-HCl, pH 7.4. For experiments involving G protein loading using
phosphorylated
2-AR, the PKA phosphorylation reaction
was terminated by the addition of a peptide inhibitor of PKA (22), and
the
2-AR was then reconstituted with heterotrimeric G
proteins and used in the [35S]GTP
S binding assay. For
quantitation of 32P-phosphorylated receptor, the
phospholipid vesicles were reclaimed by centrifugation at 350,000 × g for 40 min at 4 °C. The pellet was gently washed
once in 100 mM NaCl/10 mM Tris-HCl, pH 7.4, and
resuspended in 25 µl of Laemmli sample buffer. The entire volume was
electrophoresed on 10% polyacrylamide gels, which were then dried and
exposed to a PhosphorImager screen and quantitated using a Storm
PhosphorImager (Amersham Biosciences).
 |
RESULTS |
Effect of Mutant
2-AR PKA Phosphorylation Sites on
Gs-mediated Adenylyl Cyclase Activation in CHO
Cells--
We had originally identified Serines 261, 262, 345, and 346 of the
2-AR as putative PKA phosphorylation sites,
because they occur in classic consensus PKA phosphorylation site motifs
RRSS on the intracellular portions of the receptor (10). Based on previously published data, we expected that PKA-mediated
phosphorylation of the
2-AR would attenuate this
receptor's ability to activate adenylyl cyclase, because this is
classically a Gs-mediated pathway for the
2-AR (22). Therefore, we expected that a
2-AR mutant that mimics a constitutively
dephosphorylated receptor (four Ser to Ala mutations, or A-4) would
exhibit robust agonist-induced signaling to adenylyl cyclase, similar
to the wild type receptor. Conversely, a receptor that mimics the
PKA-phosphorylated
2-AR (four Ser to Asp mutations, or
D-4) would be expected to be impaired in its ability to activate
adenylyl cyclase. To evaluate this hypothesis, we created stably
transfected Chinese hamster ovary (CHO) fibroblast lines expressing
either the wild type, D-4, or A-4
2-AR. Individual cell
lines with comparable receptor expression levels (roughly 250 fmol/mg
as assayed by 125I-cyanopindolol binding) were used, which
was significantly greater than endogenous
-receptor expression
(5-10 fmol/mg).
We initially measured the ability of isoproterenol to stimulate
adenylate cyclase in membranes prepared from each of these cell lines.
As shown in Fig. 1, the wild type
2-AR produces robust cAMP accumulation. The A-4
2-AR maximally stimulated adenylate cyclase activity to
a slightly greater (~20%) extent than wild type receptor, and its
dose-response curve was shifted slightly (~3-fold) to the left. In
contrast, the D-4
2-AR barely stimulated enzyme activity
above basal levels. The level of cAMP production by endogenous
-receptors in CHO cells under these conditions was insignificant
compared with that obtained from
2-AR
overexpression.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 1.
Adenylyl cyclase activation in membranes from
CHO cells expressing wild type or PKA mutant
2-ARs. Adenylyl cyclase activity
was determined using membranes prepared from CHO-stable cell lines
expressing either the wild type, D-4, or A-4 2-AR.
15-min incubations were performed in the presence of the indicated
concentrations of isoproterenol. The results are expressed as -fold
activation over basal for each cell line. The data are presented
as mean ± S.E. from n = 3 independent experiments
performed in triplicate. The basal adenylyl cyclase activities
(mean ± S.E.) are 25 ± 2, 20 ± 2, and 45 ± 4 pmol/mg/min for the wild type, D-4, and A-4 2-AR lines,
respectively. The EC50 values are 1.5 × 10 7, 9.5 × 10 8, and 5 × 10 8 M for the wild type, D-4, and A-4
2-AR lines.
|
|
To assess what effect, if any,
2AR coupling to
Gi would have on cAMP accumulation, we performed
dose-response experiments in intact CHO cells expressing the wild type
and each of the mutant receptors in the presence and absence of
pre-treatment with pertussis toxin (PTX). As shown in Fig.
2, PTX had no effect on wild
type and A-4
2-AR-stimulated cAMP production. In
contrast, D-4
2-AR mediated cAMP production was
significantly increased by PTX pre-treatment, and this effect became
more pronounced at higher agonist concentrations (~50% increase in
cAMP production). However, even in the presence of PTX, cAMP production
by the D-4
2-AR only reached 36% of the level produced
by wild type
2-AR stimulation. These results suggest that the D-4 mutant may be impaired in cAMP production for two distinct
reasons. First, there is a decrease in its ability to activate
Gs, and second, there is an increase in its ability to activate Gi, as compared with the wild type receptor. In
the whole cell cAMP assays, which were performed in the presence of the cAMP phosphodiesterase inhibitor IBMX, the D-4 mutant was about 25% as active as the wild type
2-AR. Forskolin-mediated
cAMP production was not significantly different between the various cell lines (data not shown).

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 2.
Pertussis toxin increases D-4
2-AR cAMP production but does not
affect wild type or A-4 2-AR cAMP
production. The three panels (A, wt; B, D-4;
C, A-4 2-AR) represent data from
n = 7-9 independent cAMP dose-response curves
(mean ± S.E.). Cells were stimulated for 10 min with varying
concentrations of isoproterenol in the presence and absence of
pertussis toxin pre-treatment (100 ng/ml overnight), and the intracellular cAMP levels were determined.
The results are expressed as picomoles of cAMP/mg of protein. The
EC50 values were 4 × 10 9, 1.9 × 10 8, and 1.5 × 10 8 M for
the wild type, D-4, and A-4 2-AR lines, respectively,
and were not significantly altered by pertussis toxin treatment.
|
|
Effect of Mutating
2-AR PKA Phosphorylation Sites on
Gi-mediated ERK Activation in CHO Cells--
Because the
2-ARs containing mutations at consensus PKA
phosphorylation sites had differing abilities to induce cAMP
accumulation in CHO cells, we next examined the ability of
isoproterenol to activate the ERK MAPK pathway (a known PTX-sensitive
signal) in these different receptor cell lines. As shown in Fig.
3A, stimulation of CHO cells
expressing the wild type
2-AR with 1 µM
isoproterenol for 5 min induced significant ERK 1/2 phosphorylation. As
reported previously for other cell lines (5, 23),
2-AR-mediated ERK activation was inhibited by
pre-treatment with PTX in CHO cells (decreased by 75%).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 3.
Phospho-ERK activation by wild type and PKA
mutant 2-ARs in CHO stable cell
lines. A, cells were stimulated with 1 µM
isoproterenol for 5 min and pre-treated with pertussis toxin (100 ng/ml
overnight) where indicated. The upper panel depicts a
representative Western blot probed with an anti-phospho-ERK antibody to
determine the levels of active ERK in the cell lysate. The lower
panel depicts quantitation of four independent experiments
(mean ± S.E.), with data normalized by defining the wild type
receptor signal as 100%. B, cells were stimulated with 1 µM phorbol 12-myristate 13-acetate for 5 min and
pre-treated with pertussis toxin (100 ng/ml overnight) where indicated.
The upper panel depicts a representative Western blot probed
with an anti-phospho-ERK antibody to determine the levels of active ERK
in the cell lysate. The lower panel depicts quantitation of
four independent experiments (mean ± S.E.), with data normalized
by defining the wild type receptor signal as 100%.
|
|
As shown in Fig. 3A, the D-4
2-AR-expressing
cell line had a significantly greater ability to activate ERK 1/2,
compared with the wild type
2-AR, in response to agonist
(~2.5-fold enhancement), and this signal is also PTX-sensitive. The
PTX-insensitive component of the ERK 1/2 signal is likely due to the
additional influence of Gs activation and/or cAMP
generation on pathways leading to ERK 1/2 activation (24-26). A cell
line expressing the A-4
2-AR at comparable levels did
not significantly activate ERK in response to isoproterenol
stimulation. There was no significant difference in the ability of
phorbol 12-myristate 13-acetate (1 µM) to activate ERK
between the cell lines, and this signal was not affected by pre-treatment with PTX, demonstrating that ERK pathways are intact in
all the cell lines. Quantitation of these data is shown in Fig.
3B. Total ERK protein levels were comparable among the cell lines (data not shown).
Coupling of
2-AR PKA Phosphorylation Site Mutants to
Gs and Gi in a Purified, Recombinant
Reconstituted System--
To determine the G protein coupling
specificity of the wild type and PKA mutant receptors, we expressed and
purified recombinant receptors from Sf9 cells. We also purified
recombinant G
s and G
i-1 from E. coli and endogenous G
subunits from bovine brain. We then
reconstituted the purified receptors with either purified heterotrimeric Gs or Gi in phospholipid
vesicles. The ability of the receptor to interact with the G protein
was assayed by [35S]GTP
S binding to the G
subunit
in the presence, or absence, of isoproterenol. Basal levels of
activation due to spontaneous G protein nucleotide turnover were
determined for each experiment (in the absence of receptor) and
subtracted from all subsequent calculations. This system allows for the
direct determination of relative coupling efficiencies between
receptors and different G proteins. Fig.
4 shows that agonist stimulation of both
the wild type and A-4
2-ARs results in robust activation
of Gs over a 15-min time course. In contrast, agonist
stimulation of the D-4
2-AR reveals significant
impairment in its ability to couple to Gs. The D-4 mutant
is roughly 75% impaired in inducing Gs activation at the
15-min time point, compared with the wild type
2-AR.
This correlates well with the decreased cAMP production stimulated by
this receptor in CHO cells, as we would expect, because adenylyl cyclase activation is Gs-mediated.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 4.
Gs coupling of the wild type and
PKA mutant 2-ARs. Purified
receptor was reconstituted with heterotrimeric Gs in
phospholipid vesicles and assayed for G protein activation by the
ability to bind [35S]GTP S in the presence or absence
of isoproterenol over a 15-min time course. The data are presented as
mean ± S.E. for 4-6 independent experiments and fit to a
single-site binding hyperbolic curve.
|
|
Because the D-4
2-AR is better able to activate the
PTX-sensitive ERK MAPK pathway in CHO cells, we reasoned that the D-4 mutant would be better able to couple to PTX-sensitive G proteins. To
evaluate this, we reconstituted the purified D-4 mutant and wild type
2-ARs with heterotrimeric Gi-1 protein in
phospholipid vesicles and assayed the agonist-promoted
[35S]GTP
S binding to the G
subunit. Fig.
5 shows that the wild type
2-AR has a small, but significant, level of
agonist-mediated Gi coupling. However, the D-4
2-AR has significantly increased coupling to
Gi even in the absence of agonist, as compared with the
wild type
2-AR. This high level of basal coupling was
further increased by isoproterenol stimulation (up to 6-fold the wild type signal) and was modestly decreased by administration of the inverse agonist ICI-118,551, suggesting receptor-regulated
responses.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 5.
Gi coupling of the wild type and
D-4 PKA mutant 2-AR. Purified
receptor was reconstituted with heterotrimeric Gi-1 in
phospholipid vesicles and assayed for G protein activation by the
ability to bind [35S]GTP S in the presence or absence
of isoproterenol over a 15-min time course. The data are presented as
mean ± S.E. for 4-6 independent experiments and fit to a
single-site binding hyperbolic curve.
|
|
PKA Phosphorylation of Recombinant
2-AR Decreases
Gs Coupling and Increases Gi Coupling in a
Reconstituted System--
Because the PKA phosphorylation site mutant
2-ARs (serines 261, 262, 345, and 346 mutated) have
different signaling characteristics from the wild type
2-AR when expressed in CHO cells, we next wanted to
confirm that these mutants represented the characteristics of either an
endogenously PKA-phosphorylated receptor or a constitutively dephosphorylated receptor. To confirm that we had correctly identified the relevant PKA sites within the
2-AR, we overexpressed
and purified the wild type, D-4, and A-4
2-ARs from
baculovirus-infected Sf9 cells. The receptors were purified to
similar specific activities (~17,000 pmol/mg) and reconstituted into
phospholipid vesicles for in vitro characterization.
The in vitro phosphorylation assays depicted in Fig.
6 show that the wild type
2-AR is phosphorylated by both PKA and GRK2 to similar
stoichiometries of 2.3 and 2.6 mol of Pi/mol of receptor, respectively. When compared with the wild type, the mutant receptors were phosphorylated by GRK2 to a similar stoichiometry of 2.12 mol of
Pi/mol (consistent with previously published data (27)), but the PKA phosphorylation of the mutants was decreased to 0.75 mol of
Pi/mol of receptor. Therefore, serines 261, 262, 345, and 346 are relevant phosphorylation sites on the
2-AR
specifically for PKA. The residual PKA phosphorylation seen in the
mutants is most likely due to phosphorylation of non-consensus sites
under these in vitro conditions. In support of this
interpretation, when expressed in cells labeled with 32P,
the PKA-site mutant
2-AR is phosphorylated by GRK2, but
has no measurable phosphorylation by PKA (28). We also assayed the purified receptors for affinity for the agonist isoproterenol by
125I-cyanopindolol competition binding and found no
significant difference in the affinities of any of the purified
receptors for isoproterenol (data not shown).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 6.
2-AR mutants have
decreased PKA phosphorylation in vitro. In
vitro phosphorylation assays of the wild type and PKA site mutant
2-ARs by either PKA or GRK2. Purified receptor
reconstituted in phospholipid vesicles was phosphorylated by purified
kinase in the presence of [ -32P]ATP. The receptor was
separated by SDS-PAGE and the incorporated phosphate was quantitated by
PhosphorImager analysis. The upper panel shows the
quantitation of moles of Pi/mol of receptor from three
independent experiments (mean ± S.E.). The lower panel
depicts a representative autoradiograph of the radiolabeled receptor.
Data are shown for the D-4 mutant. The A-4 mutant was the same (not
shown).
|
|
The PKA site mutations of the
2-AR were initially made
because the sensitivity of the ERK MAPK signal in cells to the PKA inhibitor H-89 suggested the idea that PKA phosphorylation of the
2-AR was necessary for this pathway's activation.
However, there is some controversy over the mechanism of H-89, because at higher concentrations it appears to function as a
-receptor antagonist (29). Both the cellular and in vitro data for the D-4
2-AR suggest that it mimics a constitutively
PKA-phosphorylated
2-AR, because it is impaired in its
Gs signaling and enhanced in its Gi
signaling. To test the G protein-coupling properties of a
PKA-phosphorylated wild type
2-AR directly, we
PKA-phosphorylated the wild type
2-AR in
vitro and reconstituted the receptor with purified heterotrimeric
G proteins for coupling studies. Control phosphorylation reactions,
carried out in the absence of ATP, were used to determine the wild type
2-AR coupling under these conditions. As shown in Fig.
7A, PKA phosphorylation of the
wild type
2-AR decreases the receptor's ability to
cause agonist-promoted Gs activation by roughly 50%. In
stark contrast, the PKA-phosphorylated receptor is enhanced in its
ability to activate Gi-1 by ~6-fold (Fig. 7B).
It is noteworthy that, unlike the D-4
2-AR, the
PKA-phosphorylated receptor does not display a high level of
constitutive Gi coupling but is nonetheless able to reach
levels of agonist-induced coupling to Gi-1 that are
virtually identical to those achieved by the D-4 mutant
2-AR.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 7.
PKA phosphorylation of the wild type
2-AR decreases Gs coupling
and increases Gi coupling. Purified wild type
2-AR was in vitro-phosphorylated by PKA and
then reconstituted with either heterotrimeric Gs
(upper panel) or Gi-1 (lower panel)
in phospholipid vesicles and assayed for G protein activation by the
ability to bind [35S]GTP S in the presence or absence
of isoproterenol over a 15-min time course. Mock phosphorylation
reactions were performed in the absence of ATP. The stoichiometry of
receptor phosphorylation was 1.5 ± 0.3 for the Gs
experiments and 1.34 ± 0.13 for the Gi experiments
(mean ± S.E.). The data are presented as mean ± S.E. for
three independent experiments and fit to a single-site binding
hyperbolic curve.
|
|
 |
DISCUSSION |
The
2-AR has classically been viewed as a
prototypic Gs-coupled receptor, whose signaling properties
are largely mediated by the generation of intracellular cAMP and the
subsequent activation of PKA. Recently, it has been shown that, in
addition to its classical signaling via cyclic AMP, the
2-AR is also capable of activating the ERK MAPK pathway
(30, 31). Activation of ERK by the
2-AR proceeds via
multiple pathways, with a subset of these inhibited by pertussis toxin
(PTX), indicating that they are mediated by Gi/Go (5, 23, 24, 32). Cellular studies suggest
that PKA may be able to regulate the Gs and Gi
coupling of the
2-AR. For example,
2-AR
mediated activation of ERK, although PTX-sensitive, appears to
require prior activation of PKA, because a chemical inhibitor of PKA
(H-89) blocks
2-AR-mediated ERK activation (5). These
data support the hypothesis that phosphorylation of a PKA substrate is
necessary for
2-AR-mediated Gi activation.
However, the precise intracellular targets of PKA remain undefined.
The central hypothesis of this work is that PKA-mediated
phosphorylation of the
2-AR itself allows for the
generation of PTX-sensitive signals from the receptor by both
decreasing Gs and increasing Gi coupling.
Previously, the
2-AR has been shown to be a substrate
for PKA phosphorylation (33). Moreover, in vitro GTPase
assays have shown that PKA phosphorylation of the
2-AR
decreases the ability of the receptor to activate Gs by ~50% (22). These experiments did not, however, examine the ability of phosphorylation to alter coupling to other G protein isoforms.
Accordingly, to achieve a definitive assessment, we established an
entirely reconstituted system of purified, recombinant components and
assessed whether phosphorylation of the
2-AR by PKA
could regulate the receptor's coupling to Gs and
Gi. We undertook three approaches to assess this
hypothesis. First, we mimicked PKA phosphorylation by replacing the
consensus serine PKA phosphorylation sites of the
2-AR
with aspartate residues and examined the effect of these mutations on
Gs- and Gi-mediated signals. Second, we validated our mutant receptor-G protein coupling data in an in vitro reconstituted system. Finally, we phosphorylated the
2-AR with PKA and assessed the ability of the
phosphorylated receptor to couple to G proteins relative to the
non-phosphorylated receptor. Whether assessed with mutant receptors in
a cellular system or with purified recombinant mutant receptors or
PKA-phosphorylated
2-ARs in a reconstituted system, all
three approaches provided congruent sets of data consistent with our hypothesis.
The slight differences in the behavior of the A-4 receptor in different
assay systems are likely due to two offsetting effects of the mutation
of Ser-261 and Ser-262 located within a key G protein coupling
region of the receptor (34). On the one hand, the mutations eliminate
any desensitization attributable to PKA-mediated phosphorylation of the
receptor (10). On the other hand, as demonstrated in the reconstitution
studies in which the receptors can be studied in the absence of other
regulatory influences, the Ser
Ala mutations (Fig. 4) somewhat
diminish coupling of the receptors to Gs. As a result, such
mutants of the
2-AR may appear slightly superactive or
slightly impaired in their cAMP-generating capacity depending on the
details of the assay, such as adenylyl cyclase versus whole
cell cAMP, time of stimulation with agonist, cell type, etc.
In our membrane adenylate cyclase assays, the A-4 mutant showed a
modest increase in Vmax (20%) and
EC50 for isoproterenol (3-fold). In our whole cell cAMP
assays, A-4 showed no significant difference from wild type in
Vmax and a slight decrease in EC50 for isoproterenol (3-fold).
These results are consistent with previous studies using PKA site
mutants of the
2-AR. In this laboratory, both Liggett
et al. (35) and Hausdorff et al. (10), working
with Chinese hamster fibroblast (CHW) cells, found no
significant difference between the A-4 and wild type receptor in either
EC50 or Vmax for
isoproterenol-stimulated cyclase activity or cAMP production, although
a statistically insignificant increase in Vmax
for A-4 (~25%) was noted by Liggett et al. These
investigators also noted a significant increase in cAMP
generated by A-4 in whole cell cAMP assays but only after 15 min of
incubation with isoproterenol when desensitization had occurred. Our
whole cell cAMP experiments were done at 10 min, and, like Liggett
et al., we observed no significant difference in cAMP at
that time point.
Yuan et al. (36) also examined the adenylyl
cyclase-stimulating activity of a related
2-adrenergic
receptor mutant, in which only serines 261 and 262 were changed to Ala.
Using L cells, they found no significant change in the
EC50, whereas Vmax was modestly
(30%) increased. More detailed examination of the coupling efficiency
of the mutant receptor, however, using quantitation of high and low
affinity state agonist binding and GTP shifts, indicated that the
mutant was somewhat uncoupled, consistent with our data. Thus, our
current as well as previous adenylate cyclase and whole cell cAMP data
with Ser
Ala PKA mutants of the
2-adrenergic receptor all indicate that such mutant receptors are modestly impaired
in Gs coupling and in desensitization.
The most interesting and significant findings of the present studies,
however, relate to the characteristics of the novel Ser
Asp
(D-4) receptor and PKA-phosphorylated receptor. In the adenylyl cyclase
and whole cell cAMP assays, D-4 was markedly impaired with respect to
Gs coupling and enhanced in its Gi coupling, as
evidenced by the enhancement of D-4 receptor-stimulated cAMP production
in PTX-treated cells. The impaired coupling to Gs was confirmed in the reconstitution experiments. This effect of receptor phosphorylation to not only diminish coupling to Gs but to
enhance coupling to Gi (which inhibits adenylyl cyclase)
provides an additional mechanism by which PKA phosphorylation of the
receptor can "desensitize" cAMP generation in response to
-agonists.
The requirement for PKA phosphorylation of the
2-adrenergic receptor for Gi coupling was
further revealed in the whole cell ERK activation assays and in the
reconstitution experiments. In the CHO cells, D-4 was considerably more
efficacious than the wild type receptor in mediating pertussis
toxin-sensitive (i.e. Gi-dependent)
ERK activation, whereas, strikingly, A-4 was completely devoid of
activity. Similarly, in the reconstitution experiments D-4 showed
markedly enhanced coupling to Gi. Particularly striking was
the similarity between the D-4 mutant and the PKA-phosphorylated
2-AR in the reconstituted system. They both demonstrated
a 6-fold increase in Gi coupling over the
non-phosphorylated wild type
2-AR. With respect to
Gs coupling, the D-4 mutant was impaired 75% and the
PKA-phosphorylated
2-AR was impaired by 50% compared with non-phosphorylated wild type
2-AR.
The somewhat greater constitutive, i.e. agonist-independent,
activity of the D-4 mutant compared with the phosphorylated receptor with respect to Gi activation, and its somewhat greater
impairment with respect to Gs activation likely reflect the
greater number of added negative charges on the D-4 mutant compared
with the phosphorylated receptor. These extra negative charges could
alter the D-4 mutant receptor's conformation to further hinder
Gs activation and to increase basal signaling to
Gi. We had initially created the D-4 mutant, in part,
because the comparable A-4 mutant had already been shown to have no
measurable phosphorylation by PKA in cells (28). Thus, we expected no
further PKA-mediated phosphorylation of the D-4 mutant. It can be
reasonably argued that a D-2 mutant might more accurately reflect the
phosphorylation stoichiometry observed in our in vitro
assays. However, concerns regarding which two serines to mutate and the
fact that the remaining two serines could be phosphorylated would make
D-2 mutant analysis less informative.
PKA-mediated "switching" of
2-AR coupling from
Gs to Gi provides a mechanism by which
Gi-mediated signals can be generated by the
2-AR. Previous studies using chemical inhibitors and
assays of downstream signaling events also support such a mechanism. Prior work has shown that small peptides are capable of interacting with and activating G proteins in vitro (37-39). Small
synthetic peptides (14-22 amino acids) corresponding to portions of
the third intracellular loop of the
2-AR have been shown
to cause Gs activation in vitro. One of these
peptides, containing two of the putative phosphorylation sites for PKA,
when phosphorylated by PKA, showed a decreased ability to stimulate
Gs loading and an increased ability to promote
Gi loading compared with non-phosphorylated peptide (40).
These experiments suggest a role for PKA phosphorylation of the
2-AR at these sites in mediating
Gi-dependent signaling. However, the data
presented here represent the first direct demonstration of altered
2-AR G protein coupling specificity by PKA
phosphorylation of the intact receptor alone.
The phenomenon of a classically Gs-coupled receptor
altering its G protein coupling by "switching" its G protein
specificity is a novel finding with numerous, potentially important
implications. From the standpoint of GPCR pharmacology, this mechanism
provides further evidence that the third intracellular loop and
proximal tail of the receptor are important in determining the extent
and specificity of G protein coupling (34). Alterations to these regions such as phosphorylation or point mutation have the potential to
significantly alter the signaling events downstream of the receptor.
The alteration of a receptor's G protein coupling specificity by
PKA-mediated receptor phosphorylation may not, however, be unique to
the
2-AR and may have significant consequences for other
GPCRs. A specific example involves the vasoactive intestinal peptide
receptor in pancreatic acinar cells, where a typically Gs-coupled receptor appears to evoke
Gi-mediated responses in a manner dependent on PKA
activation (41). A more recent example involves the mouse prostacyclin
receptor, which is normally Gs-coupled but can induce
Gi- and Gq-mediated signals in a manner
dependent on PKA activity. Furthermore, this effect is blocked by
mutation of a consensus PKA site within the prostacyclin receptor
(42).
This switching mechanism represents a novel means of modulating
a signal from a Gs-coupled receptor. This could represent a
form of negative feedback where the PKA that is activated by the
Gs pathway phosphorylates the receptor and thus causes
enhanced Gi activation to limit further cAMP production. Of
potentially greater interest, this may be a mechanism by which the
2-AR is able to activate a number of PTX-sensitive
signals. These signals include ERK activation, anti-apoptotic signaling
via Akt in cardiac myocytes, and transactivation of receptor tyrosine
kinases (5-7). These Gi-mediated signals appear to be
critically involved in the physiologically important phenomenon of
cardiac myocyte hypertrophy, which is one of the earliest pivotal
changes in heart failure of a number of etiologies (8, 43, 44).
Understanding this mechanism may lead to novel therapeutic approaches
allowing for blockade of the hypertrophic growth signals in clinical
situations of chronic adrenergic receptor stimulation while leaving
other important aspects of receptor signaling intact.
 |
ACKNOWLEDGEMENTS |
We thank Darrell Capel for providing expert
assistance in protein purification. We also thank Yehia Daaka, Kristen
Pierce, and Richard Premont for helpful discussion and critical reading of the manuscript, and Donna Addison and Julie Turnbough for excellent secretarial assistance.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grant RO1 HL16037 (to R. J. L.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
An Investigator of the Howard Hughes Medical Institute. To whom
correspondence should be addressed. Tel.: 919-684-2974; Fax: 919-684-8875; E-mail: lefko001@receptor-biol.duke.edu.
Published, JBC Papers in Press, June 12, 2002, DOI 10.1074/jbc.M202753200
 |
ABBREVIATIONS |
The abbreviations used are:
2-AR,
2-adrenergic receptor;
GPCR, G protein-coupled receptor;
ERK, extracellular signal-regulated kinase;
PKA, protein kinase A;
TEV, tobacco etch virus;
PTX, pertussis toxin;
GRK, G protein-coupled
receptor kinase;
CHO, Chinese hamster ovary;
MAPK, mitogen-activated
protein kinase;
PMA, phorbol 12-myristate 13-acetate;
IBMX, 3-isobutyl-1-methylxanthine;
GTP
S, guanosine
5'-3-O-(thio)triphosphate.
 |
REFERENCES |
| 1.
|
Stiles, G. L.,
Caron, M. G.,
and Lefkowitz, R. J.
(1984)
Physiol. Rev.
64,
661-743[Free Full Text]
|
| 2.
|
Cerione, R. A.,
Staniszewski, C.,
Benovic, J. L.,
Lefkowitz, R. J.,
Caron, M. G.,
Gierschik, P.,
Somers, R.,
Spiegel, A. M.,
Codina, J.,
and Birnbaumer, L.
(1985)
J. Biol. Chem.
260,
1493-1500[Abstract/Free Full Text]
|
| 3.
|
Rubenstein, R. C.,
Linder, M. E.,
and Ross, E. M.
(1991)
Biochemistry
30,
10769-10777[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Morgan, H. E.,
and Baker, K. M.
(1991)
Circulation
83,
13-25[Free Full Text]
|
| 5.
|
Daaka, Y.,
Luttrell, L. M.,
and Lefkowitz, R. J.
(1997)
Nature
390,
88-91[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Maudsley, S.,
Pierce, K. L.,
Zamah, A. M.,
Miller, W. E.,
Ahn, S.,
Daaka, Y.,
Lefkowitz, R. J.,
and Luttrell, L. M.
(2000)
J. Biol. Chem.
275,
9572-9580[Abstract/Free Full Text]
|
| 7.
|
Zhu, W. Z.,
Zheng, M.,
Koch, W. J.,
Lefkowitz, R. J.,
Kobilka, B. K.,
and Xiao, R. P.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
1607-1612[Abstract/Free Full Text]
|
| 8.
|
Zou, Y.,
Komuro, I.,
Yamazaki, T.,
Kudoh, S.,
Uozumi, H.,
Kadowaki, T.,
and Yazaki, Y.
(1999)
J. Biol. Chem.
274,
9760-9770[Abstract/Free Full Text]
|
| 9.
|
Gudermann, T.,
Schoneberg, T.,
and Schultz, G.
(1997)
Annu. Rev. Neurosci.
20,
399-427[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Hausdorff, W. P.,
Bouvier, M.,
O'Dowd, B. F.,
Irons, G. P.,
Caron, M. G.,
and Lefkowitz, R. J.
(1989)
J. Biol. Chem.
264,
12657-12665[Abstract/Free Full Text]
|
| 11.
|
Samama, P.,
Cotecchia, S.,
Costa, T.,
and Lefkowitz, R. J.
(1993)
J. Biol. Chem.
268,
4625-4636[Abstract/Free Full Text]
|
| 12.
|
Bouvier, M.,
Hnatowich, M.,
Collins, S.,
Kobilka, B. K.,
Deblasi, A.,
Lefkowitz, R. J.,
and Caron, M. G.
(1988)
Mol. Pharmacol.
33,
133-139[Abstract]
|
| 13.
|
Pitcher, J. A.,
Touhara, K.,
Payne, E. S.,
and Lefkowitz, R. J.
(1995)
J. Biol. Chem.
270,
11707-11710[Abstract/Free Full Text]
|
| 14.
|
Benovic, J. L.,
Shorr, R. G.,
Caron, M. G.,
and Lefkowitz, R. J.
(1984)
Biochemistry
23,
4510-4518[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Caron, M. G.,
Srinivasan, Y.,
Pitha, J.,
Kociolek, K.,
and Lefkowitz, R. J.
(1979)
J. Biol. Chem.
254,
2923-2927[Free Full Text]
|
| 16.
|
Cerione, R. A.,
Strulovici, B.,
Benovic, J. L.,
Lefkowitz, R. J.,
and Caron, M. G.
(1983)
Nature
306,
562-566[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Lee, E.,
Linder, M. E.,
and Gilman, A. G.
(1994)
Methods Enzymol.
237,
146-164[Medline]
[Order article via Infotrieve]
|
| 18.
|
Casey, P. J.,
Graziano, M. P.,
and Gilman, A. G.
(1989)
Biochemistry
28,
611-616[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Cerione, R. A.,
Codina, J.,
Benovic, J. L.,
Lefkowitz, R. J.,
Birnbaumer, L.,
and Caron, M. G.
(1984)
Biochemistry
23,
4519-4525[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Fields, T. A.,
and Casey, P. J.
(1995)
J. Biol. Chem.
270,
23119-23125[Abstract/Free Full Text]
|
| 21.
|
Northup, J. K.,
Smigel, M. D.,
and Gilman, A. G.
(1982)
J. Biol. Chem.
257,
11416-11423[Free Full Text]
|
| 22.
|
Pitcher, J.,
Lohse, M. J.,
Codina, J.,
Caron, M. G.,
and Lefkowitz, R. J.
(1992)
Biochemistry
31,
3193-3197[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Pierce, K. L.,
Maudsley, S.,
Daaka, Y.,
Luttrell, L. M.,
and Lefkowitz, R. J.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
1489-1494[Abstract/Free Full Text]
|
| 24.
|
Gutkind, J. S.
(1998)
J. Biol. Chem.
273,
1839-1842[Free Full Text]
|
| 25.
|
de Rooij, J.,
Zwartkruis, F. J.,
Verheijen, M. H.,
Cool, R. H.,
Nijman, S. M.,
Wittinghofer, A.,
and Bos, J. L.
(1998)
Nature
396,
474-477[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Wu, J.,
Dent, P.,
Jelinek, T.,
Wolfman, A.,
Weber, M. J.,
and Sturgill, T. W.
(1993)
Science
262,
1065-1069[Abstract/Free Full Text]
|
| 27.
|
Fredericks, Z. L.,
Pitcher, J. A.,
and Lefkowitz, R. J.
(1996)
J. Biol. Chem.
271,
13796-13803[Abstract/Free Full Text]
|
| 28.
|
Cong, M.,
Perry, S. J.,
Lin, F. T.,
Fraser, I. D., Hu, L. A.,
Chen, W.,
Pitcher, J. A.,
Scott, J. D.,
and Lefkowitz, R. J.
(2001)
J. Biol. Chem.
276,
15192-15199[Abstract/Free Full Text]
|
| 29.
|
Penn, R. B.,
Parent, J. L.,
Pronin, A. N.,
Panettieri, R. A.,
and Benovic, J. L.
(1999)
J. Pharmacol. Exp. Ther.
288,
428-437[Abstract/Free Full Text]
|
| 30.
|
Lazou, A.,
Bogoyevitch, M. A.,
Clerk, A.,
Fuller, S. J.,
Marshall, C. J.,
and Sugden, P. H.
(1994)
Circ. Res.
75,
932-941[Abstract/Free Full Text]
|
| 31.
|
Crespo, P.,
Cachero, T. G., Xu, N.,
and Gutkind, J. S.
(1995)
J. Biol. Chem.
270,
25259-25265[Abstract/Free Full Text]
|
| 32.
|
Schmitt, J. M.,
and Stork, P. J.
(2000)
J. Biol. Chem.
275,
25342-25350[Abstract/Free Full Text]
|
| 33.
|
Benovic, J. L.,
Pike, L. J.,
Cerione, R. A.,
Staniszewski, C.,
Yoshimasa, T.,
Codina, J.,
Caron, M. G.,
and Lefkowitz, R. J.
(1985)
J. Biol. Chem.
260,
7094-7101[Abstract/Free Full Text]
|
| 34.
|
O'Dowd, B. F.,
Hnatowich, M.,
Regan, J. W.,
Leader, W. M.,
Caron, M. G.,
and Lefkowitz, R. J.
(1988)
J. Biol. Chem.
263,
15985-15992[Abstract/Free Full Text]
|
| 35.
|
Liggett, S. B.,
Bouvier, M.,
Hausdorff, W. P.,
O'Dowd, B.,
Caron, M. G.,
and Lefkowitz, R. J.
(1989)
Mol. Pharmacol.
36,
641-646[Abstract]
|
| 36.
|
Yuan, N.,
Friedman, J.,
Whaley, B. S.,
and Clark, R. B.
(1994)
J. Biol. Chem.
269,
23032-23038[Abstract/Free Full Text]
|
| 37.
|
Rubenstein, R. C.,
Wong, S. K.,
and Ross, E. M.
(1987)
J. Biol. Chem.
262,
16655-16662[Abstract/Free Full Text]
|
| 38.
|
Higashijima, T.,
Uzu, S.,
Nakajima, T.,
and Ross, E. M.
(1988)
J. Biol. Chem.
263,
6491-6494[Abstract/Free Full Text]
|
|